Vinorelbine

Generic Name
Vinorelbine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C45H54N4O8
CAS Number
71486-22-1
Unique Ingredient Identifier
Q6C979R91Y
Background

Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...

Indication

Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .

Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...

Associated Conditions
Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
Associated Therapies
-
Clinical Trials
Related News

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

First Posted Date
2021-01-06
Last Posted Date
2024-08-09
Lead Sponsor
Seagen Inc.
Target Recruit Count
502
Registration Number
NCT04697628
Locations
🇺🇸

Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States

🇺🇸

Maryland Oncology Hematology, P.A., Columbia, Maryland, United States

🇮🇹

Fondazione Policlinico Universitario Agostino, Roma, Other, Italy

and more 189 locations

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

First Posted Date
2020-12-23
Last Posted Date
2020-12-23
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
71
Registration Number
NCT04681911
Locations
🇨🇳

Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Phase 3
Conditions
Breast Cancer
Interventions
Drug: Docetaxel
Drug: Navelbine
First Posted Date
2020-12-14
Last Posted Date
2020-12-14
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
50
Registration Number
NCT04665986

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

First Posted Date
2020-11-12
Last Posted Date
2024-05-23
Lead Sponsor
University of Birmingham
Target Recruit Count
1672
Registration Number
NCT04625907
Locations
🇬🇷

University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece

🇮🇱

Rambam Health Care Campus, Haifa, Israel

🇮🇱

Hadassah University Medical Centre, Jerusalem, Israel

and more 125 locations

Evolutionary Therapy for Rhabdomyosarcoma

First Posted Date
2020-05-14
Last Posted Date
2024-11-28
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
28
Registration Number
NCT04388839
Locations
🇺🇸

Connecticut Children's Medical Center, Hartford, Connecticut, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States

and more 15 locations

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

First Posted Date
2020-03-13
Last Posted Date
2020-03-13
Lead Sponsor
Fudan University
Target Recruit Count
316
Registration Number
NCT04307147
Locations
🇨🇳

Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients

First Posted Date
2020-03-11
Last Posted Date
2023-06-28
Lead Sponsor
European Institute of Oncology
Target Recruit Count
162
Registration Number
NCT04304352
Locations
🇮🇹

European Institute of Oncology, Milan, Italy

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

First Posted Date
2020-03-10
Last Posted Date
2020-03-10
Lead Sponsor
Fudan University
Target Recruit Count
550
Registration Number
NCT04302441
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Phase 1
Recruiting
Conditions
Rhabdomyosarcoma
Interventions
Drug: Vinorelbine
Drug: Mocetinostat
First Posted Date
2020-03-06
Last Posted Date
2024-06-12
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
38
Registration Number
NCT04299113
Locations
🇺🇸

Rebecca Phelan, Los Angeles, California, United States

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

First Posted Date
2020-03-05
Last Posted Date
2020-03-05
Lead Sponsor
Fudan University
Target Recruit Count
178
Registration Number
NCT04296162
Locations
🇨🇳

Zhi-Ming Shao, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy